MDS: higher risk patients may still benefit from ICT

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Iron chelating therapy (ICT) with oral deferasirox (DFX) in patients with higher risk myelodysplastic syndromes (MDS) delivered outcomes comparable to those seen with ICT on low-risk disease.

Why this matters

  • Iron overload is common in transfusion-dependent patients, but ICT is generally not recommended in patients with higher risk MDS.  

Study design

  • 51 patients with transfusion-dependent, intermediate-to-very high-risk MDS, according to the revised international prognostic scoring system, treated with the oral iron chelating agent DFX.
  • Study to investigate the viability of ICT with DFX in 51 patients with transfusion-dependent, intermediate/very high-risk MDS; median age: 65 y.
  • 36 of the patients received concomitant azacitidine.
  • Funding: Italian Ministry of Health....